Statements (60)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
5
|
gptkbp:bfsParent |
gptkb:Ciba-Geigy
|
gptkbp:activities |
inhibits mitochondrial electron transport
|
gptkbp:appointed_by |
oral tablet
|
gptkbp:approves |
gptkb:2000
gptkb:FDA |
gptkbp:availability |
widely available in pharmacies
|
gptkbp:clinical_trial |
Phase III
malaria treatment malaria prophylaxis |
gptkbp:contains |
atovaquone
proguanil |
gptkbp:contraindication |
hypersensitivity to components
severe renal impairment |
gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
gptkbp:dosage_form |
gptkb:tablet
1 tablet daily for prevention 4 tablets for treatment on first day |
gptkbp:duration |
3 days for acute malaria
daily for prevention |
gptkbp:education |
take with food
report any severe side effects complete full course of treatment |
gptkbp:formulation |
fixed-dose combination
|
https://www.w3.org/2000/01/rdf-schema#label |
Malarone
|
gptkbp:ingredients |
atovaquone
proguanil hydrochloride |
gptkbp:interacts_with |
gptkb:warfarin
certain antiretroviral drugs |
gptkbp:invention |
gptkb:2015
|
gptkbp:is_available_on |
generic version
|
gptkbp:is_effective_against |
P. malariae
P. ovale high against P. falciparum moderate against P. vivax |
gptkbp:is_monitored_by |
renal function
liver function |
gptkbp:is_used_for |
treatment of malaria
prevention of malaria |
gptkbp:manager |
oral
|
gptkbp:marketed_as |
Malarone brand name
|
gptkbp:packaging |
blister pack
|
gptkbp:price |
varies by region
|
gptkbp:requires |
prescription only
|
gptkbp:research_focus |
combination therapies
resistance patterns |
gptkbp:shelf_life |
3 years
|
gptkbp:side_effect |
headache
nausea abdominal pain diarrhea liver enzyme elevation skin rash |
gptkbp:storage |
room temperature
|
gptkbp:suitable_for |
severe liver disease
pregnant women without consultation children under 5 kg travelers to malaria-endemic areas |
gptkbp:takes_place_in |
food to enhance absorption
|